Modelling the tumour microenvironment for the evaluation of new immuno-oncology therapies

Our world-class immunology team with the lead of our Scientific Director of Immunology, Robert Benson, has produced a research poster presenting in vitro primary human immune cell assays for assessing the effectiveness of new immuno-oncology therapies on various immune cell types.

Immunotherapy has transformed the treatment of cancer, allowing targeting and effective activation of the immune system to fight tumour cells. Despite success in some, not all patients respond to current therapies, warranting the need for new and more effective options.

Different subtypes of primary human immune cells, such as regulatory T cells, NK cells, macrophages, T cells and exhausted T cells, play important roles in the tumour microenvironment (TME) therefore assays using these cells can provide valuable insight into the evaluation of new immuno-oncology therapies. 

In our research poster we share invaluable data showing various aspects of the tumour microenvironment and in vitro assays. 

Improving immuno-oncology therapies

In vitro assays with primary human immune cells are powerful tools for evaluating the impact of new immuno-oncology therapies on immune cell types that are relevant to cancer. These assays can help elucidate the mechanisms of action of the new therapies and assess their potential for clinical benefit, facilitating the discovery and development of new immuno-oncology therapies that can improve cancer treatment quality for patients.

We can give you specialist support across a range of in vitro human bioassays specifically created for the tumour microenvironment covering regulatory T cells, macrophages, NK cells, T cells including exhausted and effector T cells and tumour cells.

If you have any questions regarding our research results presented in the poster or would like to discuss potential studies about the TME, feel free to reach out to our immunologists.